Effects of β-glucan Yeast Extract on Melanoma Progression, Tumor Infiltration, and Immune Modulation
By
Bruno Miranda dos Santos Oliveira
Fernanda Paloma Duarte Trierweiler
Bianca Ramos Mesquita
Jose Nathan Andrade Muller Da Silva
Washington Luís dos Santos
José Mengel
Fabíola Cardillo
April 20, 2026
Clinical Scorecard: Effects of β-glucan Yeast Extract on Melanoma Progression, Tumor Infiltration, and Immune Modulation
At a Glance
Category Detail
Condition Melanoma Key Mechanisms Immunomodulation via β-glucan from Saccharomyces cerevisiae Target Population Patients with melanoma, particularly those with advanced stages Care Setting Experimental models and potential clinical applications
Key Highlights
β-GESc treatment increased spleen size and splenocyte counts. Enhanced immune activation indicated by increased MHC class II expression and germinal center formation. Improved survival rates and reduced tumor growth in treated mice. Higher counts of CD4+ and CD8+ T cells producing IFN-γ and TNF-α post-treatment. Potential to overcome resistance to checkpoint inhibitors in advanced melanoma. Guideline-Based Recommendations
Diagnosis
Histopathology remains the gold standard for melanoma diagnosis. Complementary methods include immunohistochemistry and genomic profiling. Management
Surgical excision is effective for localized melanoma (stages I and II). Consider novel therapies like β-GESc for advanced melanoma. Monitoring & Follow-up
Regular assessment of tumor progression and immune response. Risks
Advanced melanoma has a high mutation rate and can evade immune responses. Patient & Prescribing Data
Patients with melanoma, especially those resistant to conventional therapies.
β-GESc may enhance immune response and improve outcomes in melanoma treatment.
Clinical Best Practices
Utilize β-GESc as an adjunct therapy in melanoma treatment. Monitor immune cell populations and cytokine profiles in patients receiving β-GESc. References
